Advertisements

Clopixol Depot

Quick links to important sections

Clopixol Depot

Selected form

Advertisements
Advertisements

Treatment option: Schizophrenia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Clopixol Depot

Quick Facts

Property Description
Active Ingredient Zuclopenthixol decanoate
Form Long-acting intramuscular injection (LAI)
Pharmacological Class Typical antipsychotic (Neuroleptic)
General Use Long-term mental stability (Maintenance treatment)
Origin Synthetic (Thioxanthene ester)

What Type of Medicine is Clopixol Depot?

Clopixol Depot is a prescription-only medication classified as a typical antipsychotic, which belongs to the broader neuroleptic drug class. The active component, zuclopenthixol, is a synthetic derivative categorized under the thioxanthene chemical family. The drug’s primary function is to help stabilize thought processes by modulating certain chemical signals in the brain, a mechanism recognized for managing severe psychotic conditions. This medication is intended for use in maintaining psychiatric stability, providing consistent, long-term support for adults with chronic mental health disorders.


Composition and Form: Why is it a Depot Injection?

The Depot designation defines the unique nature of this medication: a long-acting intramuscular injection (LAI), distinguishing it from short-acting or oral forms. Its formulation contains the active ingredient as zuclopenthixol decanoate, an ester of zuclopenthixol, dissolved in a medium-chain triglyceride oil vehicle. This specific oil solution and chemical structure are designed to create a drug reservoir, or depot, deep within the muscle after intramuscular administration. This specialized ester form allows for a prolonged duration of action, unlike standard aqueous injections.


How Does the Long-Acting Form Benefit Treatment?

The unique form provides the core benefit of sustained action, making Clopixol Depot a preferred choice for maintenance treatment. The formulation relies on a slow enzymatic breakdown process that continuously releases therapeutic levels of zuclopenthixol into the bloodstream over several weeks. This steady delivery is vital for ensuring consistency in patient management, particularly for those requiring continuous therapeutic support for long-term conditions.

Advertisements

What side effects are possible with Clopixol Depot?

Official Safety Profile and Adverse Reactions

The safety profile of Clopixol Depot (zuclopenthixol decanoate) is documented based on frequency classifications defined by regulatory authorities, grouping adverse effects by the system or organ they affect.

Classification Examples of Documented Effects
Very Common (ge1/10) Somnolence, akathisia (restlessness), hypersalivation, hyperkinesia, hypokinesia.
Common (ge1/100 to <1/10) Headache, dizziness, tremor, dry mouth, constipation, tachycardia, and weight gain.

Adverse effects are categorized within System-Organ Classes (SOCs), with prominent documentation in Nervous System Disorders (including extrapyramidal symptoms) and Gastrointestinal Disorders.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight the potential for serious adverse reactions, which include Neuroleptic Malignant Syndrome (NMS), a rare but severe condition, and the risk of QT prolongation which is a specific concern for the cardiac system. Tardive Dyskinesia, a serious movement disorder, is associated with prolonged periods of use, while many common extrapyramidal reactions are noted to occur early in treatment.

Special safety considerations are documented for certain populations. Older adults are noted to be at an increased risk for sedation, hypotension, and falls. The medicine is contraindicated in conditions such as circulatory collapse and coma. Caution is also officially advised for individuals with pre-existing conditions like epilepsy and cardiovascular disorders, and those with hepatic impairment.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The long-acting nature of Clopixol Depot makes overdose symptoms officially documented as unlikely to occur. However, regulatory sources outline the manifestations of an overdosage with the active substance, zuclopenthixol. Documented clinical signs may include central nervous system depression, presenting as extreme drowsiness (somnolence) or coma, and movement disturbances known as extrapyramidal symptoms, alongside temperature instability.

Overdose is associated with severe, potentially life-threatening outcomes affecting the cardiovascular and central nervous systems. These include dangerously low blood pressure (hypotension), circulatory shock, and significant cardiac rhythm abnormalities such as QT prolongation and cardiac arrhythmia. Because of these serious risks, official guidance states that individuals must seek immediate medical attention for a suspected overdose, and emergency services should be contacted if the person is non-responsive.

Management is limited to general supportive measures and symptomatic treatment, as regulatory information formally states that no specific antidote is known for this medication. Due to the high risk of cardiovascular complications, close monitoring of vital functions, including continuous ECG monitoring, is required in the clinical setting to observe for malignant arrhythmias. The regulatory profile emphasizes that supportive care and observation are the primary interventions in this severe event.

Advertisements

Therapeutic Uses of Clopixol Depot

The purpose of Clopixol Depot (zuclopenthixol decanoate) is intended to support adults with severe, persistent mental health conditions. As a long-acting injection, its primary therapeutic role is focused on supporting stability and assisting in the management of symptom recurrence. The depot formulation is commonly used in the maintenance treatment of schizophrenia and allied psychoses.

Therapeutic Scope and Benefits

This medication is relevant for conditions characterized by periods of heightened symptoms and is used to relieve the manifestations of chronic psychotic illnesses. Specifically, it helps address core psychotic symptoms such as delusions, hallucinations, and disturbances in thought, alongside disruptive behavioral patterns like agitation, hostility, and aggression. Addressing these symptoms helps ease the overall burden and may assist with maintaining functional stability.

Sustained Support

The primary therapeutic benefit of the depot includes its role in maintenance treatment and relapse prevention. By providing sustained action, it offers symptomatic relief through a sustained approach that is relevant for patients who face challenges with the consistent daily intake of oral medication. This formulation is relevant in the clinical context of maintenance treatment for schizophrenia and other psychoses.

“The continuous therapeutic approach assists with supporting functional stability.”


Quick Fact: Relief for Disruptive Symptoms

Clopixol Depot is generally applied across domains where additional symptomatic support is needed, primarily focusing on managing chronic psychotic illnesses and easing associated behavioral patterns, such as agitation and hostility.

Regulatory References

  1. NHS guidance on Depot Antipsychotics
Advertisements

Eligibility and Restrictions for Use

Clopixol Depot (zuclopenthixol decanoate) is restricted by official regulatory labels to specific patient populations and conditions.

Contraindications (Must Not Use)

Individuals must not use this medicine if they have a known hypersensitivity to the active substance, zuclopenthixol, or to other thioxanthenes. Use is also prohibited in patients experiencing certain acute clinical states, including:

  • Circulatory collapse.
  • Comatose states or depressed level of consciousness due to any cause (e.g., acute alcohol, barbiturate, or opiate intoxication).
  • Suspected or established subcortical brain damage.

Restricted or Not Recommended Populations

Population Regulatory Status
Children and Adolescents (< 18 yrs) Not Recommended; safety and efficacy are not established due to lack of clinical experience.
Pregnancy Should not be administered unless the expected benefit outweighs the risk. Use in the third trimester may result in adverse symptoms in the newborn.
Breastfeeding Not Recommended; the substance is excreted in breast milk.
Older Adults (Geriatrics) Use is permitted, but the initial dosage may need to be reduced to a quarter or half the normal starting dose.
Hepatic Impairment Patients with compromised liver function should receive half the recommended dosages.
Renal Impairment Patients with renal failure may require dosage reduction (half the normal dose).
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Clopixol Depot (zuclopenthixol decanoate) across several risk categories, leading to explicit restrictions on co-administration with specific agents.

Combinations to Avoid or Contraindicate

  • Acute Intoxication: Clopixol Depot is contraindicated in patients with acute intoxication from alcohol, barbiturates, or opiates, as well as in conditions involving Central Nervous System (CNS) depression.
  • QT Prolonging Agents: Co-administration with medicinal products known to significantly increase the QT interval must be avoided due to an increased risk of cardiac rhythm disturbances. Examples include certain antiarrhythmics (e.g., quinidine, amiodarone) and other antipsychotics (e.g., thioridazine).

Interactions Affecting Drug Exposure and Effects

Interaction Type Interacting Agent/Class Official Regulatory Statement
Metabolic (Decreased Clearance) CYP2D6 Inhibitors Co-administration may lead to decreased clearance of zuclopenthixol, potentially increasing plasma levels.
Pharmacodynamic (Risk Enhancement) Metoclopramide or Piperazine Concomitant use increases the risk of extrapyramidal disorder.
Pharmacodynamic (Additive Effects) CNS Depressants (e.g., alcohol, general anaesthetics) May enhance the sedative effect.
Pharmacodynamic (Antagonism) Guanethidine or similar antihypertensives Neuroleptics may block the antihypertensive effect of these compounds.
Pharmacodynamic (Neurotoxicity) Lithium Co-administration is noted to increase the risk of neurotoxicity.

Population-Specific Interaction Notes

The regulatory label notes that Clopixol Depot may modify insulin and glucose responses, requiring adjustment of antidiabetic therapy in diabetic patients. Caution is also advised when combining the medicine with agents known to cause electrolyte disturbances in individuals susceptible to QT prolongation.

Advertisements

Mechanism of Action

Clopenthixol decanoate is a pro-drug administered via intramuscular injection. Following administration, it undergoes hydrolysis, releasing the active compound, clopenthixol. The primary pharmacodynamic mechanism involves the antagonism of postsynaptic dopamine D1 and D2 receptors within the central nervous system. Clopenthixol also exhibits affinity and antagonist activity at serotonin 5-HT2A, alpha1-adrenergic, and histamine H1 receptors. The resulting receptor blockade modulates G protein-coupled signaling pathways, leading to an alteration in neuronal firing rates and neurotransmitter turnover in key pathways, specifically the mesolimbic system. The lipid-based depot formulation facilitates the sustained release of clopenthixol over several weeks. This extended pharmacokinetic profile maintains consistent receptor occupancy, ensuring continuous and stable modulation of neurobiological targets at the system level.

Advertisements

Dosage and Administration Information

Clopixol Depot is a long-acting formulation of zuclopenthixol decanoate, administered by a healthcare professional for maintenance treatment.

Official Administration Guidelines

Administration Scope Detail
Route Deep intramuscular (IM) injection into the upper outer buttock (gluteal region) or lateral thigh.
Preparation The solution is a clear, yellowish oil. Aspiration is required before injection to ensure inadvertent intravascular entry does not occur, as is standard practice for oil-based injections.
Injection Volume Injection volumes greater than 2 mL should be distributed between two separate injection sites.

Dosing and Frequency

Dosing Rule Detail
Initial/Test Dose Typically 100 mg to assess tolerance in patients not previously on depot formulations. The second injection is given at least one week later.
Maintenance Dose The usual dose is 200–400 mg (1–2 mL of 200 mg/mL solution) administered every two to four weeks. The interval and dose are adjusted based on the patient's individual response to treatment.
Maximum Dose The maximum single dose is 600 mg.

Age and Condition Adjustments

  • Older Patients: Initial dosage may need to be reduced to one-quarter or one-half of the normal starting dose.
  • Hepatic Impairment: Patients with compromised liver function should receive half the recommended dosages, and serum-level monitoring may be advised.
  • Renal Impairment: For patients with renal failure, the dosage should be reduced to half the normal dosage.
  • Paediatric Population: Use is not recommended due to lack of clinical experience.

When transferring from oral Clopixol or Clopixol Acuphase, the initial oral medication should be gradually withdrawn over several days after the first Depot injection is given.

Advertisements

Recent Clinical Evidence

Clopixol Depot, the long-acting injectable (LAI) formulation of zuclopenthixol decanoate, is primarily indicated for the maintenance treatment of schizophrenia and related psychoses. Recent clinical evidence, including systematic reviews, generally supports the drug's role as an effective maintenance therapy, especially for patients with a history of poor adherence to oral medication.

Efficacy and Comparative Studies

Clinical trials and retrospective studies examining long-acting injectable antipsychotics have consistently shown that depot formulations are associated with a reduced risk of relapse and re-hospitalization compared to oral antipsychotics, particularly in real-world, non-randomized settings where medication adherence is a significant challenge. This advantage is largely attributed to the assurance of consistent dosing provided by the depot injection.

When comparing Clopixol Depot (a first-generation LAI) with other antipsychotic depots, available data suggests its effectiveness in preventing relapse may be comparable to, or even slightly greater than, some other first-generation and some second-generation LAIs, though the evidence is often limited by the quality and design of available studies.

Safety and Tolerability Profile

Clopixol Depot's safety profile is consistent with other typical antipsychotic medications. The most commonly reported side effects include extrapyramidal symptoms (EPSEs), such as tremors, parkinsonism, and akathisia, and sedation. In some comparisons, Clopixol Depot has been associated with a potentially higher burden of adverse effects, including EPSEs, compared to certain other antipsychotics. Other serious, though rare, risks associated with the drug class include Neuroleptic Malignant Syndrome (NMS) and potential QTc interval prolongation, requiring careful clinical monitoring.

Common Adverse Effects Serious/Rare Side Effects
Extrapyramidal symptoms (EPSEs) Neuroleptic Malignant Syndrome (NMS)
Sedation, Somnolence QTc Interval Prolongation
Hypersalivation, Dry Mouth Venous Thromboembolism (VTE)
Weight changes Cerebrovascular Adverse Events (in elderly dementia patients)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Clopixol Depot (FAQ)


Q: Is Clopixol Depot the same as regular Clopixol tablets?

No, they are different formulations. Clopixol Depot is a long-acting injection (LAI) that contains zuclopenthixol decanoate, which is a pro-drug (an inactive form that the body converts to the active drug). Regular Clopixol tablets contain zuclopenthixol dihydrochloride, the active drug itself, for daily oral use. This difference in form is what allows the Depot injection to work over several weeks.


Q: Are there any long-term side effects of taking Clopixol Depot?

Regulatory documents indicate that while many side effects may happen early on, Tardive Dyskinesia (a condition causing involuntary movements) is a serious risk associated with prolonged, long-term use of the medication. Official information also notes a potential for hormonal changes, such as elevated prolactin levels, with extended use. These effects are typically managed and monitored by a healthcare provider.


Q: Can Clopixol Depot affect a person's ability to drive?

Official product information advises caution regarding activities requiring concentration. Because common side effects include dizziness, somnolence (drowsiness), and blurred vision, official advice indicates that operating machinery or driving should be avoided until the patient knows how the medicine affects them.


Q: How long does it take for the effects of Clopixol Depot to start working?

Clopixol Depot is primarily intended for maintenance of stable symptoms, rather than immediate relief during a crisis. Official pharmacokinetic data shows that levels of the active drug increase within the first week after the injection. The full, consistent therapeutic benefit is usually established after the first few maintenance injections.


Q: Does Clopixol Depot interact with common pain relievers like ibuprofen?

Regulatory documents advise general caution when combining Clopixol Depot with other medicines that may affect the body’s ability to clot blood, which includes common non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen. Any combined use should be discussed with a healthcare professional.


Q: What happens if I miss a scheduled dose of Clopixol Depot?

The official management guideline emphasizes the importance of receiving the injection as close to the scheduled date as possible. Regulatory guidelines suggest contacting a healthcare professional immediately after realizing a dose has been missed so they can provide guidance on the subsequent steps.


Q: Does Clopixol Depot cause sexual side effects?

Yes, regulatory documents list adverse events such as decreased libido and issues like ejaculation failure or erectile dysfunction. These effects are often associated with elevated levels of the hormone prolactin (hyperprolactinaemia) and are typically noted to be reversible upon stopping the medication.


Q: Are there any common foods or supplements to avoid while on this medicine?

Official interaction warnings mainly focus on other medicines and alcohol. There is no specific regulatory warning against common foods. However, the use of supplements known to cause electrolyte disturbances (such as low magnesium or potassium) should be monitored closely, as this could impact the heart rhythm.


Q: What is the general success rate mentioned in studies for Clopixol Depot?

Official information does not define the medication's success with a single percentage rate. Instead, studies and regulatory documents highlight that the consistent dosing provided by the depot injection is associated with a reduced risk of relapse and re-hospitalization when compared to oral antipsychotics.


Q: How long does Clopixol Depot stay in your system?

The drug is engineered to be released gradually from the muscle over a period of weeks. Official pharmacokinetic data shows that after release, the active compound is primarily metabolized (broken down) in the liver. It is then eliminated from the body largely via the faeces, with a smaller amount removed by the kidneys.


Q: Is Clopixol Depot a medicine that has withdrawal symptoms if stopped?

Yes. Regulatory information states that abruptly stopping the medication may be followed by acute withdrawal symptoms. These symptoms can include feelings of nausea, vomiting, sweating, restlessness, and difficulty sleeping. Discontinuation or dose reduction should only be done under the supervision of a healthcare professional.


Q: Are there any specific injection site reactions that are common with Clopixol Depot?

Official adverse reaction lists indicate that pain at the injection site is a commonly reported effect following administration. Any reaction should be reported to the administering professional.


Q: Can Clopixol Depot interact with herbal remedies or multivitamins?

While the primary warnings focus on prescription drugs, caution is advised for any supplement or herbal remedy, such as St. John's Wort, that is known to affect liver enzymes (like CYP2D6). If a supplement can cause electrolyte disturbances, it must also be used with care due to potential cardiac risks.


Q: What should be done if I feel sick right after receiving the injection?

If you experience any signs of a severe allergic reaction (like swelling of the face or difficulty breathing) or symptoms of Neuroleptic Malignant Syndrome, such as high fever, rigid muscles, or confusion, seeking immediate emergency medical attention is the critical step. For less severe symptoms, you should contact your healthcare provider immediately.


Q: Is it common for people to need a high dosage of Clopixol Depot?

Official product information provides a usual maintenance range (e.g., 200–400 mg) and defines a maximum single dose (e.g., 600 mg). The final dose is determined by the healthcare provider based on individual therapeutic response, ensuring stability for each patient.


Q: What does 'antipsychotic' mean in simple terms when talking about this drug?

Clopixol Depot belongs to a class of medicines called antipsychotics (or neuroleptics). According to official documents, these medicines work by acting on the brain’s chemical signals, primarily blocking dopamine receptors. This action helps to balance thought processes, which assists in managing symptoms of severe mental health conditions like psychosis.


Q: What is the longest period of time people typically stay on Clopixol Depot?

The medication is officially indicated for maintenance treatment of chronic psychiatric conditions. This means it is intended for consistent, long-term use to ensure continuous therapeutic support and stability, and there is no predetermined official maximum duration of therapy.


Q: How quickly can Clopixol Depot be stopped if there is a severe reaction?

In the rare event of a severe adverse reaction, such as Neuroleptic Malignant Syndrome (NMS), the official regulatory advice is to immediately stop the administration of the neuroleptic drug. The healthcare team will then provide urgent medical care and manage the consequences of the long-acting nature.


Q: Does Clopixol Depot change or alter your personality?

The official side effect profile lists changes in emotional state, such as anxiety, agitation, and depression. While the document does not state that the medicine changes your core personality, if a patient feels a significant change is occurring, this should be discussed with a healthcare provider.


Q: Does this medication have a black box warning in the US?

Yes, regulatory documents in the United States, such as the FDA Prescribing Information, include a Boxed Warning (sometimes called a black box warning). This warning concerns an increased risk of death when antipsychotic drugs are used to treat behavior issues in older adults with dementia.


Q: How does the body break down and eliminate Clopixol Depot?

After injection, the oil-based pro-drug is converted into the active drug, zuclopenthixol, primarily through an enzymatic process called hydrolysis. The resulting active drug is then metabolized in the liver, partially by the CYP2D6 enzyme, and is primarily eliminated from the body via the faeces.


Q: Can you still take other psychiatric medications while on Clopixol Depot?

Official interaction guidelines show that combining Clopixol Depot with other psychiatric medicines is possible but requires professional caution. Specific combinations are restricted or avoided if they increase the risk of heart rhythm issues (QT prolongation), excessive sedation, or movement disorders.


Q: Is Clopixol Depot known to affect focus or concentration?

Yes, official regulatory documents list disturbance in attention as a common side effect of the medication. Additionally, other common effects such as somnolence (drowsiness) and dizziness can negatively impact a person’s overall ability to focus and concentrate.


Q: What should a patient do if they think they are experiencing a rare side effect?

Regulatory requirements state that patients should contact a healthcare professional (doctor, pharmacist, or nurse) or seek emergency medical care immediately, depending on the severity of the reaction. The official process also stipulates that you should report the side effect using the national reporting scheme for adverse reactions.

Advertisements

How should Clopixol Depot be stored and disposed of?

Storage and Disposal of Clopixol Depot

The storage and disposal of Clopixol Depot (zuclopenthixol decanoate) must adhere strictly to regulatory conditions to ensure the product's stability.

Storage Requirements

The product does not require any special temperature storage conditions, though it is often recommended to store it below 25 C.

Condition Requirement
Light Protection Ampoules must be kept in the outer carton to protect the contents from light.
Child Safety Must be kept out of the sight and reach of children.
Stability The solution must be used immediately after the ampoule is opened; any unused solution must be discarded.

Disposal Instructions

Any unused medicine, expired product, or related waste material must be disposed of in accordance with local requirements. The medicine should not be disposed of in household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clopixol Depot found in:

A-Z Index: